Today's focus

[Hi-Tech Development Performance Report: Net profit due to mother increased 85.28% year-on-year in 2023]

Hi-Tech Development released its 2023 annual performance report. During the reporting period, the company achieved operating income of 7.975 billion yuan, an increase of 21.37% over the previous year; net profit attributable to shareholders of listed companies was 369 million yuan, an increase of 85.28% over the previous year. Basic earnings per share were $1.05. Small financial note: Q3 net profit was 161 million yuan. Based on this calculation, Q4 net profit was 115 million yuan, down 28% from the previous month.

[Wulianban Lihang Technology: Currently, there is no revenue from the low-altitude economy business]

Lihang Technology issued a stock trading risk warning notice. The company's main business is aircraft ground support equipment, aircraft testing and inspection equipment, aircraft process equipment, aircraft parts processing, and aircraft parts assembly. The company's business has not changed since listing. The company currently has no revenue from the low-altitude economy business. Investors are invited to pay attention to the risk of conceptual hype.

[Yao Ming Kang De: Using capital of 49.99 million yuan to buy back shares today]

Yao Ming Kangde announced that on March 11, 2024, the company repurchased the company's shares for the first time through centralized bidding transactions. The number of shares repurchased was 937,079 shares, accounting for 0.032% of the company's total share capital as of the date of this announcement. The highest repurchase price was RMB 54.95 yuan/share, and the minimum repurchase price was RMB 51.54 yuan/share, and the total capital used was RMB 49.99 million.

[Foci Pharmaceutical: The factory price of its main proprietary Chinese medicine products will increase by an average of 9%]

Forci Pharmaceuticals announced that due to reasons such as rising raw materials and production costs, the company decided to adjust the factory price of its main proprietary Chinese medicine products starting March 11, 2024, with an average price increase of 9%.

Investments & Contracts

[Sailun Tire: Plans to invest US$251 million in tire project in Indonesia]

Sailun Tire announced that the company plans to invest in the construction of a “project with an annual output of 3.6 million radial tires and 37,000 tons of off-road tires” in Indonesia. The total investment for the project was US$251 million.

[Shandong Gold: Plans to acquire 70% of Changtai Mining's shares for 470 million yuan]

Shandong Gold announced that it intends to sign an “Equity Transfer Agreement” with all shareholders of Baotou Changtai Mining Co., Ltd. to acquire 70% of Changtai Mining's shares at a transaction price of 470 million yuan.

[Competition Information: The holding subsidiary plans to purchase land use rights for 411 million yuan and build an R&D headquarters in East China]

Saiyi Information announced that the holding subsidiary Saiyi Real Estate plans to purchase land use rights through the listing and sale of state-owned construction land use rights, and build a digital innovation enabling development platform for Saiyi Information's “East China Centralized Delivery Center+East China Marketing Management Center+East China Digital Industry Talent College” by constructing Saiyi Information's “East China Centralized Delivery Center+East China Digital Industry Talent College”. Saiyi Real Estate's total investment in purchasing land and constructing the East China R&D headquarters is approximately 411 million yuan, all owned or self-funded.

[Yongli Co., Ltd.: Plans to increase capital for a wholly owned Thai company to build its own factory]

Wynn Co., Ltd. announced that it plans to increase the capital of its wholly-owned subsidiary Parkway Precision Thailand by 550 million baht through its wholly-owned subsidiary Zhaoyuan Hong Kong (about RMB 111 million at the March 11 exchange rate) to further meet the construction and working capital needs of Parkway Precision's own factory in Thailand, and effectively enhance the company's size, overall competitiveness and overall resilience to risks. The successful implementation of Parkway Precision's own factory project in Thailand will help enhance the company's scale and position in the precision molding industry.

[Shenma Co., Ltd.: Plans to increase capital in Nylon Technology]

Shenma Co., Ltd. announced that it intends to jointly sign a “Capital Increase and Share Expansion Agreement” with Hengshen Synthetic Fiber and Dongxin Coking for Henan Shenma Nylon Technology Co., Ltd. The three parties intend to increase the capital of Nylon Technology according to the shareholding ratio in cash to allocate the capital for Nylon Technology's 100,000 tons/year nylon 6 civil wire phase II (60,000 tons/year) project, with a total capital increase of 200 million yuan.

Increase/decrease holdings & repurchases

[Riyadh: Plans to repurchase shares for 30 million yuan to 60 million yuan]

Riyadh announced that it plans to repurchase shares for 30 million yuan to 60 million yuan. The repurchase price will not exceed RMB 7.40 per share.

[Jin Baize: Plans to buy back shares for 30 million yuan to 60 million yuan]

Jin Baize announced that it plans to repurchase shares for 30 million yuan to 60 million yuan, and the repurchase price of shares will not exceed 29.00 yuan/share.

[Tianshan Electronics: Shareholders and their concerted actors plan to reduce the company's shares by no more than 3%]

Tianshan Electronics announced that Li Xiaoyong, a shareholder holding a total of 8.98% of shares, and his co-actors, Zhongjin Lanhai, plan to reduce their total holdings of the company's shares by no more than 1% of the total number of shares of the company through centralized bidding, and reduce their total holdings of the company's shares by no more than 2% of the total number of shares through bulk transactions.

[Shouhua Gas: Shareholders plan to reduce holdings by no more than 3%]

Shouhua Gas announced that Tibet Kejian and its co-actors intend to reduce the company's shares by no more than 3%.

Operation & Performance

[Jiangsu Guoxin: 2023 net profit of 1,881 billion yuan, a year-on-year increase of 3014.74%]

Jiangsu Guoxin announced a quick performance report. Revenue in 2023 was 34.572 billion yuan, up 6.38% year on year; net profit was 1,871 billion yuan, up 3014.74% year on year. During the reporting period, prices in the coal market fell, and marginal revenue from the coal and electricity business increased. At the same time, the energy sector strictly controlled costs and expenses, continued to improve quality and efficiency, and achieved significant growth in performance; the financial sector's business development was stable, earnings continued to grow, and profit contributions further increased.

[New capital: net profit of 755 million yuan in 2023, a year-on-year increase of 1586.23%]

New Guodu released a quick performance report. Operating revenue in 2023 was 3.801 billion yuan, down 11.94% year on year; net profit was 755 million yuan, up 1586.23% year on year; and basic earnings per share were 1.44 yuan. The company's net profit growth rate in 2023 was high, mainly due to the fact that net profit in 2022 was affected by impairment of goodwill and capital refund expenses in non-operating expenses, which led to a low base. Excluding the effects of the above factors, the company's net profit growth rate in 2023 was about 110.07%.

[Radico Laser: Net profit of 224 million yuan in 2023 increased 446.87% year-on-year]

Radical Laser released a performance report. In 2023, it achieved total operating revenue of 3.68 billion yuan, an increase of 15.40% year on year; net profit of 224 million yuan, an increase of 446.87% year on year. The number of lasers sold in 2023 was about 159,000 units, an increase of 16.39% over the previous year.

[Linglong Tire: Net profit to mother increased 374.66% year-on-year in 2023]

Linglong Tire announced that in 2023, revenue was 20.065 billion yuan, up 18.58% year on year; net profit was 1,386 billion yuan, up 374.66% year on year; basic earnings per share were 0.95 yuan. In 2023, the company achieved a cumulative year-on-year increase in sales volume of 26.1%, of which passenger car tires with high gross profit increased by 28.34% year-on-year.

[Shanghai Xinyang: Net profit of 167 million yuan in 2023 increased 213.41% year-on-year]

Shanghai Xinyang released a performance report. In 2023, it achieved operating income of 1,212 billion yuan, an increase of 1.4% year on year; net profit of 167 million yuan, an increase of 213.41% year on year.

[Straits shares: net profit of 434 million yuan in 2023 increased by 185.26% year-on-year]

Straits Co., Ltd. released a quick performance report. Operating revenue in 2023 was 3,932 billion yuan, up 32.67% year on year; net profit was 434 million yuan, up 185.26% year on year. During the reporting period, the tourism market economy recovered, people's willingness to travel increased, and the Qiongzhou Strait ferry market was improving. The cumulative passenger volume of imported and exported vehicles increased significantly in 2023, and the share of passengers exported from the company's port increased year on year.

[Tianfu Communications: Net profit of 730 million yuan in 2023 increased by 81.14% year-on-year]

Tianfu Communications released its 2023 annual performance report. The company achieved total operating revenue of 1,939 billion yuan, an increase of 62.07% year on year; net profit of 730 million yuan, an increase of 81.14% year on year. During the reporting period, the company achieved revenue and profit growth. This is mainly due to the company's forward-looking layout and increased R&D investment, which enables new products to quickly meet customer needs. At the same time, the company continues to upgrade its information system and automation, reduce costs and increase efficiency at the Jiangxi production base, and the capacity utilization rate has improved markedly.

[Saiwei Era: Net profit of 339 million yuan in 2023 increased by 83.23% year-on-year]

Saiwei Times released its 2023 annual performance report. During the reporting period, the company achieved operating revenue of 6.564 billion yuan, an increase of 33.7% year on year; net profit of 339 million yuan, an increase of 83.23% year on year. During the reporting period, the company's apparel brand matrix was continuously improved, and the apparel business achieved relatively rapid growth. The adverse factors faced by the non-apparel accessories category have gradually been mitigated, such as inventory clean-up nearing completion, falling initial freight rates, etc. At the same time, after category streamlining and R&D strengthening, the non-apparel accessories business market performed well.

[Guanjie Technology: Net profit of 278 million yuan in 2023 increased 220.19% year-on-year]

Guanjie Technology announced that the company's total revenue for 2023 was 54.597 billion yuan, down 11.77% year on year; net profit was 278 million yuan, up 220.19% year on year; basic earnings per share were 0.06 yuan. During the reporting period, the company maintained its dominant position in intelligent display manufacturing. The overall gross margin of the product increased steadily, and profitability improved markedly over the same period last year.

[Miao Exhibition: Net profit of 191 million yuan in 2023 increased 278.51% year-on-year]

Mio Exhibition announced that in 2023, revenue was 835 million yuan, up 139.72% year on year; net profit was 191 million yuan, up 278.51% year on year; basic earnings per share were 1.26 yuan. During the reporting period, the company's operating income and net profit increased dramatically, mainly due to a sharp increase in revenue from overseas self-hosted exhibitions.

[Caida Securities: Net profit increased 100.27% year-on-year in 2023]

Caida Securities announced that in 2023, the company achieved total operating income of 2,311 million yuan, an increase of 667 million yuan over the same period of the previous year, an increase of 40.57%; net profit attributable to shareholders of listed companies was 606 million yuan, an increase of 304 million yuan, or 100.27% over the same period last year. During the reporting period, the number of the company's asset management plans, the scale of assets under management, and revenue from the asset management business all increased significantly year-on-year.

[Youxunda: 2023 net profit of 191 million yuan increased 93.7% year-on-year]

Youxunda announced that in 2023, revenue was 1,097 million yuan, up 7.42% year on year; net profit was 191 million yuan, up 93.7% year on year; basic earnings per share were 0.96 yuan.

[Peace Bird: Net profit returning to mother increased 127.1% year-on-year in 2023]

Peacebird released its 2023 annual performance report. During the reporting period, the company achieved net profit of 420 million yuan, an increase of 127.1% over the previous year; achieved net profit withholding of 290 million yuan and resumed growth, mainly due to a significant year-on-year increase in retail discounts and a year-on-year increase in gross sales margin; at the same time, the company continued to promote cost reduction and fee control. The total expenses declined year on year, and profitability gradually improved.

[Shanghai Film: Net profit of 120 million yuan in 2023, loss of 330 million yuan for the same period last year]

Shanghai Film announced a net profit of 120 million yuan in 2023 and a loss of 330 million yuan for the same period last year.

[Zuli Pharmaceutical: Net profit is expected to increase by 40.58%-50.84% year-on-year in the first quarter]

Zuoli Pharmaceutical announced that net profit for the first quarter is expected to be 137 million yuan to 147 million yuan, an increase of 40.58%-50.84% over the previous year; sales of Wuling capsules and Lingze tablets continued good market growth, and sales of traditional Chinese medicine formula tablets increased significantly year-on-year as the number of registered varieties increased.

[Longhua New Materials: net profit of 248 million yuan in 2023 increased 95.32% year-on-year]

Longhua New Materials released a quick performance report. In 2023, the company achieved total operating revenue of about 5,021 billion yuan, an increase of 58.50% year on year; net profit was about 248 million yuan, an increase of 95.32% year on year. Basic earnings per share were $0.58. During the reporting period, the production capacity of the 360,000 tons/year high-performance polyether polyol expansion project was fully released; in 2023, the company's sales volume of polyether polyol products was about 541,600 tons, an increase of 82.91% over the same period last year. The increase in sales volume of the company's products is the main reason for the increase in performance.

[Huangshanghuang: 2023 net profit of 705.85,500 yuan, a year-on-year increase of 129.05%]

Huangshanghuang released a performance report. Operating revenue in 2023 was 1,921 billion yuan, down 1.7% year on year; net profit was 705.855 million yuan, up 129.05% year on year; basic earnings per share were 0.12 yuan.

Contract & Project Award

[Ningbo Construction Engineering: The holding subsidiary jointly won the bid for the 474 million yuan project]

Ningbo Construction Engineering announced that the holding subsidiary Municipal Group, as the consortium leader, and the consortium formed by the 11th Information Industry Electronics Design and Research Institute Technology Engineering Co., Ltd. won the bid for the Mianyang Science and Technology City Aviation Industrial Park infrastructure construction project, winning the bid price of 474 million yuan.

[Feilong Co., Ltd.: Received a designated development notice from a domestic thermal management company]

Feilong Co., Ltd. announced that it has received a designated development notice from a domestic thermal management company. The company became a development supplier for this customer's electronic water pump project in the civil sector. This electronic water pump is used in the field of liquid cooling in the large-scale machinery and equipment industry.

[Jiangsu Beiren: Received 96.8984 million yuan purchase order confirmation]

Jiangsu Beiren announced that the company received a “Purchase Order Confirmation” and “Purchase Order” from an international auto parts brand customer on the same day, and the company provided an overall solution for intelligent NEV chassis manufacturing for the target project. The tax-inclusive order amount was 96.8984 million yuan, accounting for 13.13% of the company's 2022 audited revenue.

[Exploration shares: won a total of 267 million yuan in survey and design projects]

Exploration Co., Ltd. recently received a bid notice from Guizhou Expressway Group Co., Ltd. for the “G6002 Guiyang Huancheng Expressway Expansion Project Survey Design and Survey Design Consulting GYHCKRSJ1 Section” and “G6002 Guiyang Huancheng Expressway Expansion Project Survey Design and Survey Design Consulting GYHCKRSJ3 Section”. The total bid amount was 267 million yuan, accounting for about 12.39% of the total audited revenue in 2022.

[Huaguang Huaneng: won the bid for the project of about 174 million yuan]

Huaguang Huaneng announced that the company received the “Notice of Winning Bid” from the tenderer Shandong Electric Power Construction Third Engineering Co., Ltd., confirming that the company won the bid for the “Guangzhou Zengcheng Wanglong Gas and Electricity Replacement Project EPC General Contracting Project Waste Heat Boiler and Auxiliary Equipment Procurement” project, with a bid amount of about 174 million yuan.

other

[Sinqi Pharmaceutical: Obtaining a Drug Registration Certificate for Atropine Sulfate Eye Drops]

Xingqi Pharmaceutical announced that it has obtained a drug registration certificate for atropine sulphate eye drops. The approved clinical indication is to slow the progression of myopia in children aged 6 to 12 with a spherical degree of -1.00D to -4.00D (astigmatism ≤ 1.50D, refractive error ≤ 1.50D).

[Huadong Pharmaceutical: Subsidiary HDM1005 injection approved for clinical trial]

Huadong Pharmaceutical announced that recently, China and America Huadong, a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the National Drug Administration (NMPA). The HDM1005 injection clinical trial application submitted by China and the US East China was approved, agreeing to carry out clinical trials of this product for type 2 diabetes and weight control indications.

[Kangtai Biotech: Subsidiary adsorbs tetanus vaccine begins phase III clinical trial]

Kangtai Biotech announced that the adsorbed tetanus vaccine developed by Beijing Minhai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, has completed preparations for phase III clinical trials, officially started phase III clinical trials, and recently successfully completed the enrollment of the first test subjects. Adsorbed tetanus vaccine is a vaccine prepared using tetanus toxoid adsorption with adjuvants.

[Boji Pharmaceutical: subsidiary tadalafil tablets obtained drug registration certificate]

Boji Pharmaceutical announced that “tadalafil tablets” declared by its wholly-owned subsidiary Guangzhou Boji Biomedical Technology Park Co., Ltd. have obtained the “Drug Registration Certificate” approved and issued by the State Drug Administration. This drug is used to treat male erectile dysfunction, as well as the symptoms and signs of erectile dysfunction combined with benign prostatic hyperplasia.

[Shenzhou Cell: Subsidiary Product SCTB35 Receives Drug Clinical Trial Approval]

Shenzhou Cell announced that recently, Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials for CD20 positive B-cell non-Hodgkin lymphoma indications for CD20 positive B-cell non-Hodgkin lymphoma.

[Tianyu Co., Ltd.: Subsidiary passed on-site inspection by the European Medicines Quality Administration]

Tianyu Co., Ltd. announced that the subsidiary Linhai Tianyu Pharmaceutical Co., Ltd. underwent on-site GMP inspection of the active ingredient CEP (European Pharmacopeia Suitability Certificate) by the European Medicines Quality Administration from October 18 to October 20, 2023. Recently, the company received the inspection certificate issued by EDQM, and the inspection passed successfully.